Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 112

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 112
---
 paid by investors
in the Initial Public Offering, which could cause the market price of our Common Stock to decline. Such stockholders may realize a positive
rate of return on the sale of their shares of Common Stock. On February 5, 2025, the closing prices of our Common Stock and our Public
Warrants as reported on the Nasdaq were $1.96 per share and $0.0149 per Public Warrant, respectively.

Holders of our Warrants
will be less likely to exercise their Warrants if the exercise prices of their Warrants exceed the market price of our Common Stock.
There is no guarantee that our Warrants will continue to be in the money prior to their expiration, and as such, the Warrants may expire
worthless. As such, any cash proceeds that we may receive in relation to the exercise of the Warrants overlying shares of Common Stock
being offered for sale in this prospectus will be dependent on the trading price of our Common Stock. There is no assurance that the
holders of the Warrants will elect to exercise any or all of such Warrants. As of the date of this prospectus, (i) all of the Private
Placement Warrants and Public Warrants, which have an exercise price of $1,150.00 per share, (ii) all of the Rollover Warrants, which
have an exercise price of $1,000.00 per share, and (iii) all of the Series A Common Warrants, which have a current exercise price of
$139.00 per share, are “out of the money,” meaning the exercise price is higher than the market price of our Common Stock.
Holders of such “out of the money” Warrants are not likely to exercise such Warrants. There can be no assurance that such
Warrants will be in the money prior to their respective expiration dates, and therefore, we may not receive any cash proceeds from the
exercise of such Warrants.

An active trading market for our Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our Common Stock may be extremely volatile, and stockholders could lose all or part of their investment.

The trading price of our
Common Stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which
are beyond our control, including limited trading volume. In addition to the factors discussed in this “Risk Factors”
section and elsewhere in